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Harri HemiläAbstract
Physical activity increases oxidative stress and therefore the antioxidant effects of vitamin C administration might
become evident in people undertaking vigorous exercise. Vitamin C is involved in the metabolism of histamine,
prostaglandins, and cysteinyl leukotrienes, all of which appear to be mediators in the pathogenesis of exercise-induced
bronchoconstriction (EIB). Three studies assessing the effect of vitamin C on patients with EIB were subjected to a
meta-analysis and revealed that vitamin C reduced postexercise FEV1 decline by 48% (95% CI: 33% to 64%). The
correlation between postexercise FEV1 decline and respiratory symptoms associated with exercise is poor, yet
symptoms are the most relevant to patients. Five other studies examined subjects who were under short-term,
heavy physical stress and revealed that vitamin C reduced the incidence of respiratory symptoms by 52% (95%
CI: 36% to 65%). Another trial reported that vitamin C halved the duration of the respiratory symptoms in male
adolescent competitive swimmers. Although FEV1 is the standard outcome for assessing EIB, other outcomes
may provide additional information. In particular, the mean postexercise decline of FEF50 is twice the decline of
FEV1. Schachter and Schlesinger (1982) reported the effect of vitamin C on exercise-induced FEF60 levels in 12
patients suffering from EIB and their data are analyzed in this paper. The postexercise FEF60 decline was greater
than 60% for five participants and such a dramatic decline indicates that the absolute postexercise FEF60 level
becomes an important outcome in its own right. Vitamin C increased postexercise FEF60 levels by 50% to 150%
in those five participants, but had no significant effect in the other seven participants. Thus, future research on
the effects of vitamin C on EIB should not be restricted to measuring only FEV1. Vitamin C is inexpensive and
safe, and further study on those people who have EIB or respiratory symptoms associated with exercise is warranted.
Keywords: Anti-asthmatic agents, Ascorbic acid, Cough, Histamine, Exercise-induced asthma, Forced expiratory flow
rates, Meta-analysis, Prostaglandin, Randomized controlled trial, The lungsIntroduction
Exercise-induced bronchoconstriction (EIB) describes the
acute narrowing of the airways that occurs as a result of
vigorous exercise [1-3]. The emergence of EIB depends on
the kind and level of physical activity, and also on the hu-
midity and temperature of the inhaled air [1-3].
Only about 10% of the non-asthmatic general popula-
tion suffer from EIB, whereas up to 90% of asthmatics
may suffer from EIB [2-4]. Thus EIB is a common pheno-
type of asthma. EIB is also common among competitive
athletes even if they do not have asthma, and it isCorrespondence: harri.hemila@helsinki.fi
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unless otherwise stated.particularly prevalent in endurance sports, such as run-
ning, winter sports and swimming [2,3,5].
Usually, a decline of 10% or greater in FEV1 after exer-
cise is classified as EIB, but other cut off limits have also
been used [1-3]. However, EIB is not an arbitrary dichot-
omous condition, instead there is a continuous variation
in the possible level of FEV1 decline such that the 9%
and 11% decline levels in FEV1 are not biologically dif-
ferent phenomena, although they fall on either side of
the usual cut off level. A single constant percentage
point cut off limit is thus simplistic. It is more useful to
analyze the phenomenon as a continuous variable rather
than a dichotomous variable. This issue is relevant whenhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lated to EIB.
Symptoms are much more important than laboratory
values for patients. However, the correlation between the
declines in postexercise FEV1 values and postexercise re-
spiratory symptoms is poor [4,6,7]. Therefore, respira-
tory symptoms should be recorded concurrently with
the pulmonary function tests.
The stimulus for EIB seems to be the loss of water
caused by increased ventilation. This leads to the release
of mediators such as histamine, prostaglandins and leu-
kotrienes, all of which cause bronchoconstriction [1-3,8].
Nitric oxide also plays a role in the pathogenesis of EIB
[9,10]. Finally, oxidative stress seems to play role in the
emergence of EIB [11,12].
Vitamin C: exercise and airways
Physical activity increases oxidative stress [13], and there-
fore, as an antioxidant vitamin C might have particularly
evident effects in people who are participating in vigorous
exercise. Electron spin resonance studies have shown that
vitamin C administration decreased the levels of free
radicals generated during exercise [14,15] and vitamin
C administration attenuated the increases in oxidative
stress markers caused by exercise [16-18].
The level of vitamin C in the lungs is high [19], and
vitamin C levels in alveolar macrophages and alveolar
type II cells are 30 times higher than in plasma [20].
About 10% of vitamin C in the lungs of rats is in a
lavageable form [21], but the level of vitamin C in the
bronchoalveolar lavage seems to be lower in humans
than in rats [22]. In any case, high levels of vitamin C in
the lungs imply that the vitamin may protect the lungs
against oxidative stress.
Unlike guinea pigs and humans, mice and rats are able
to synthesize vitamin C, and these species are able to in-
crease their rates of vitamin C synthesis under certain
stressful conditions. Ozone exposure in rats and mice
significantly increased vitamin C levels in bronchoalveo-
lar lavage fluid [23,24], which might serve as a protective
response to the higher oxidative stress level being en-
countered. Exposure to ozone and nitrogen dioxide
decreased lung vitamin C levels in guinea pigs, which
implies that the vitamin was consumed while it pro-
tected against the oxidants [25,26]. Vitamin C admin-
istration in guinea pigs decreased mortality caused by
ozone exposure [27,28] and vitamin C deficiency in
guinea pigs increased necrotic injury to type II lung
cells upon H2O2 treatment [29]. Exposure to ozone in
humans decreased the vitamin C level in the respiratory
tract lining fluid [30]. Thus, given that oxidative stress
seems to play a role in EIB [11,12], vitamin C might pro-
tect against EIB through non-specific antioxidant effects.
Nevertheless, there are also more specific biochemicalmechanisms through which vitamin C may influence pul-
monary functions.
Histamine is one of the mediators involved in the
pathogenesis of EIB [1-3,8]. It is released from mast
cells, which have a high concentration of vitamin C [31].
Furthermore, the release of histamine causes oxidation
of vitamin C in the mast cells [32]. In guinea pigs, a defi-
ciency of vitamin C increased histamine levels in their
plasma, urine and lungs [33,34], whereas a high dosage
of vitamin C decreased their plasma histamine levels
[35]. In vitamin C deficient guinea pigs, a single dose of
vitamin C rapidly decreased plasma and urine histamine
levels to normal levels [34]. In rats, vitamin C attenuated
the increases in histamine levels, which were caused by
various stressful conditions including cold and heat
stress [36]. Four trials conducted on humans found that
the administration of vitamin C significantly decreased
plasma histamine levels [37-40]. Vitamin C decreased
bronchoconstriction caused by histamine in living guinea
pigs [33,41-44], and it decreased contractions caused by
histamine in isolated guinea pig trachea smooth muscle
[45,46]. Finally, in guinea pigs exposed to ozone, vitamin
C decreased bronchial reactivity to histamine [47].
Prostaglandins (PGs) and leukotrienes (LTs) also partici-
pate in the pathogenesis of EIB [1-3,8]. Vitamin C deficiency
in guinea pigs increased the level of bronchoconstrictor
PGF2α in the trachea [44,48], and increased the in vitro
synthesis of PGF2α in lung microsomes [49]. Vitamin C
deficiency decreased the production of PGE2 in guinea
pig trachea [48]; PGE2 causes smooth muscle relaxation
and may protect against EIB [1,2]. Furthermore, hyper-
responsiveness to histamine in vitamin C deficient guinea
pigs was further increased by indomethacin [44], and the
relaxing effects of vitamin C on isolated guinea pig trachea
were inhibited by indomethacin [46]. Indomethacin also
blocked the effect of vitamin C on methacholine-induced
bronchoconstriction in humans [50]. The influence of
indomethacin on vitamin C effects is a further indication
that the pulmonary effects of vitamin C may be partly
mediated through the influences of vitamin C on the
PG metabolism. Furthermore, vitamin C decreased
contractions caused by PGF2α in guinea pig tracheal
tube preparations [48]. Finally, the administration of
vitamin C in humans reduced the postexercise increase
in the urinary markers of bronchoconstrictors PGD2
and cysteinyl LTs [51].
Nitric oxide (NO) has also been implicated in the patho-
genesis of EIB [9,10]. The metabolism of NO is altered in
EIB patients but it is not correlated with exercise-induced
changes in spirometry [9]. Vitamin C was reported to de-
crease the NO level in EIB patients [51].
A single oral dose of vitamin C can rapidly elevate
mucosal vitamin C levels. Nasal lavage fluid vitamin C
levels in human subjects increased by three-fold in two
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The rapid transport of ingested vitamin C to the respira-
tory tract lining fluid implies that even single doses of
vitamin C might be effective in protecting against acute
increases in oxidative stress in the airways.
FEV1 decline caused by exercise
Three randomized, double-blind, placebo-controlled cross-
over trials examined the effect of vitamin C (0.5 to 2 g/day)
on exercise-induced FEV1 decline (Table 1). The pooled ef-
fect of vitamin C (Figure 1) indicates a reduction in the
postexercise FEV1 decline of 48% (95% CI: 33% to 64%)
[54,55]. In one study, Tecklenburg et al. reported that the
postexercise FEV1 decline was 12.9% after the placebo
period, but only 6.4% after a 2-week vitamin C administra-
tion, which corresponds to 50% reduction in the postexer-
cise FEV1 decline [51] (Figure 1). In other two studies,
vitamin C was administered as a single dose 1 or
1.5 hours before the exercise test [56,57], yet the ef-
fects were the same as for the first study (Figure 1).
Thus, a single dose of vitamin C before an exercise session
appears to be sufficient to generate the same benefit as a
2-week supplementation regime. This may be explainedTable 1 Trials on vitamin C and EIB
Study [ref.] Characteristics of
Schachter & Schlesinger [56] Selection: 12 subjects with as
“all 12 subjects gav
least 20% reduction
Sex, age: 5 Males, 7 Females
Exercise test: All subjects perform
measured with an
begun at a constan
min interval cardiac
kilopondmeters pe
Exercise against pro
reached 170 beats
post-exercise at 0 a
Cohen et al. [57] Selection: 20 patients with as
at least 15%” in FEV
Sex, age: 13 Males, 7 Female
Exercise test: A 7-min exercise se
at a speed and slop
by a pulse oximete
Tecklenburg et al. [51] Selection: 8 subjects with asth
Indiana USA. All su
10%” in postexercis
and intermittent w
Sex, age: 2 Males, 6 Females
Exercise test: Each subject ran on
age predicted max
voluntary ventilatio
6-min steady state
min until volitional
15, 20, and 30 min.
value was calculateby the rapid transfer of vitamin C to the airway lining
fluids [52,53].
The three EIB trials included a total of only 40 partici-
pants. However, the trials were carried out over three
different decades and on two different continents. The
criteria for EIB differed and the mean ages of the partici-
pants were 14 years in one study [57] but 25 and 26 years
in the two other studies [51,56]. Nevertheless, all the
studies are consistent with vitamin C halving the postex-
ercise FEV1 decline (Figure 1). It is not clear how far this
estimate can be generalized, but similar findings from
such dissimilar studies indicate that vitamin C may be
effective for a wider population who suffer from EIB.
A fourth randomized cross-over trial on 8 participants
who suffered from EIB found that the combination of
0.5 g/day of vitamin C along with vitamin E significantly
decreased the FEV1 decline at 5, 15 and 30 min after ex-
ercise [58]. Although this finding is not specific to vita-
min C, it is consistent with the benefits of antioxidants.
In 5 other participants who did not suffer from EIB,
postexercise FEV1 decline was not influenced by the
combination of the vitamins [58]. This study was pub-
lished only as an abstract.participants
thma, selected from among employees of Yale University in the USA:
e a characteristic description of EIB.” All included participants had at
in FEF60 or FEF60(P) after exercise.
; mean age 26 yr (SD 5 yr).
ed the exercise studies on a cycloergometer. Cardiac frequency was
electrocardiograph. Baseline heart rate was obtained and exercise was
t speed of 20 km/h against zero workload. At the end of each one
frequency was measured and the workload was increased by 150
r min, keeping pedalling speed constant throughout the experiment.
gressively larger workloads was continued until either the heart rate
per min or the subject fatigued. Pulmonary function was assessed
nd 5 min.
thma in Israel. All of them demonstrated EIB by having a “decline of
1 after a standard exercise test.
s; mean age 14 yr (range 7 to 28 yr).
ssion using the treadmill. Each subject exercised to submaximal effort
e to provide 80% of the motional oxygen consumption as adjudged
r. Pulmonary function was assessed after an 8-min rest.
ma from a population of university students and the local community,
bjects had “documented EIB as indicated by a drop of greater than
e FEV1. “All subjects had a history of chest tightness, shortness of breath
heezing following exercise.”
; mean age 24.5 yr (SD 5 yr).
a motorized treadmill which was elevated 1% per min until 85% of
imum heart rate and ventilation exceeding 40–60% of predicted maximal
n. Subjects maintained this exercise intensity for 6 min. Following the
exercise, the grade of the treadmill continued to increase at 1% per
exhaustion. Pulmonary function was assessed post-exercise at 1, 5, 10,
The maximum percentage fall in FEV1 from the baseline (pre-exercise)
d and used as the outcome.
Figure 1 Reduction of postexercise FEV1 decline by vitamin C. The vertical lines indicate the 95% CI for the three trials that studied the effect
of vitamin C administration on EIB and the squares in the middle of the lines indicate the point estimates of the studies. An effect of 100% would
indicate full prevention of postexercise FEV1 decline. The diamond shape at the foot indicates the 95% CI for the pooled vitamin C effect: 48%
(95% CI: 33% to 64%) reduction in postexercise FEV1 decline. For example, Tecklenburg et al. reported a 12.9% FEV1 decline after placebo, but
only a 6.4% decline after the vitamin C period, which corresponds to a 50% reduction in FEV1 decline by vitamin C [51]. This figure is based on
data published in [54].
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FEV1 is the standard outcome for assessing whether a pa-
tient suffers from EIB [1-3]. However, exercise-induced
decline in FEF25-75 is twice as great as the decline in FEV1,
and therefore, FEF25-75 may provide relevant information
in addition to FEV1 data [6,7,9,10,59-63]. Furthermore,
FEF50 values essentially give the same information as
FEF25-75 [64].
Schachter and Schlesinger (1982) studied 12 partici-
pants with EIB and published the effects of a single dose
of 0.5 g vitamin C on the FEV1, PEF, and FEF60 levels on
each participant before and after the exercise test [56].
Figure 2 shows the data for 5 minutes after the exercise
test. As a pulmonary function measure, the FEF60 level
is close to the FEF50 level. On the basis of the slope of the
linear regression line (Figure 2A), vitamin C decreased the
postexercise FEV1 decline by 55% (95% CI: 32% to 78%).
The mean decline in postexercise FEV1 was 18% on the
placebo day. The greatest postexercise FEV1 decline on
the placebo-day was 52% in participant #11 (Figure 2A).
PEF is not recommended for assessing EIB, since it is
less repeatable than FEV1 [2,3]. The study by Schachter
and Schlesinger found that vitamin C had no consistent
effect on postexercise PEF decline (Figure 2B). The lin-
ear regression slope did not significantly differ from
the null effect, thus it is not shown. However, all of the
5 participants who did benefit of vitamin C as measured
by its effects on FEV1, also had a substantial postexercise
PEF decline of 20% or more on the placebo day. Thus, a
high PEF decline on the placebo day identified all the
5 participants who benefited from vitamin C as evaluated
by FEV1. This finding might have practical importance
since PEF measurements are much easier to carry out
than spirometry.
The linear regression slope indicated that vitamin C
decreased the postexercise FEF60 decline by 58% (95%
CI: 23% to 92%) (Figure 2C). The mean decline inpostexercise FEF60 was 35% on the placebo day, which is
twice the decline in FEV1 (18%). The ratio of about two
for the declines in FEF25-75 and FEV1 has been reported
previously [6,7,9,10,62,63]. The exercise-induced FEF60
decline on the placebo day was greater than 60% in 5 out
of the 12 participants, with the greatest decline being 92%
for participant #11 (Figure 2C).
A dramatic postexercise FEF60 decline in 5 participants
indicates that the absolute postexercise level of FEF60 be-
comes an important outcome in its own right. For each
of these 5 participants, the postexercise FEF60 level was
less than 1 L/s on the placebo day (Figure 2D). More-
over, vitamin C administration increased the postexer-
cise FEF60 level in these 5 participants by between 50%
and 150%. In contrast, no mean difference between the
vitamin C and placebo days was detected in the other 7 par-
ticipants. This indicates that the effect of vitamin C may be
restricted to those EIB patients who had postexercise FEF60
levels below 1 L/s.
Schachter and Schlesinger also reported the FEF60(P)
values, which were based on partial flow volume curves
[56]. The effect of vitamin C on FEF60(P) was similar to its
effects on FEF60. This analysis is shown in Additional file 1.
Finally, Schachter and Schlesinger reported the FEV1,
PEF, FEF60 and FEF60(P) values also for the time point
immediately after the exercise (0 min) [56]. At the 0 minute
data, vitamin C and placebo days differ significantly when
analyzed by linear regression (Figure 3). On the basis of the
slopes, vitamin C decreased the postexercise FEV1 changes
by 86% (95% CI: 24% to 147%), postexercise PEF changes
by 74% (95% CI: 31% to 118%), and postexercise FEF60
changes by 90% (95% CI: 9% to 171%). Postexercise
FEF60 levels were also significantly influenced by vita-
min C (P =0.003). Thus, significant effects on postexer-
cise pulmonary function changes by vitamin C can also
be seen immediately after the exercise challenge test.
This analysis is shown in Additional file 2.
Figure 2 (See legend on next page.)
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Figure 2 Effect of vitamin C on 5-min postexercise changes for different pulmonary function outcomes according to the study by
Schlesinger and Schachter [56]. Effect of vitamin C on the following 5 min after exercise: A) the postexercise FEV1 change, B) the postexercise
PEF change, C) the postexercise FEF60 change, and D) the postexercise FEF60 level. Figures 2A, B, and C show the effect of vitamin C in
percentage points (pp). For example, on the placebo-day, participant #11 had a postexercise FEV1 decline of 52%, and on the vitamin C day a
postexercise FEV1 decline of 33%, which gives the 19 pp improvement shown in Figure 2A. Figure 2D shows the effect of vitamin C in percentages.
For example, on the placebo-day, participant #11 had a postexercise FEF60 level of 0.2 L/s, and on the vitamin C day a postexercise FEF60 level
of 0.5 L/s, which gives the 150% increase shown in Figure 2D. Figure 2 uses the same identification numbers for participants as those used
in the original paper [56]. The dash lines indicate equality between vitamin C and placebo. If vitamin C had no effect, the observations
would be located randomly and symmetrically around the dash lines. The continuous lines indicate the regression lines. In Figure 2A, the
addition of the placebo-day postexercise FEV1 change to the model containing the intercept improved the model fit by χ2(1 df) =16.5 (P =0.0001).
In Figure 2B, the slope did not significantly differ from the null effect and therefore the regression line is not shown. In Figure 2C, addition of the
placebo-day postexercise FEF60 change to the model containing the intercept improved the model fit by χ2(1 df) =10.5 (P =0.001). In Figure 2D, adding
the two spline segments with the knot at 1.1 L/s to the model containing only the intercept improved the model fit by χ2(2 df) = 24.7 (P = 0.000004).
For the statistical methods of Figure 2, see Additional file 1.
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In evidence-based medicine (EBM) the primary focus of
interest is on clinically relevant outcomes, including symp-
toms such as cough, sore throat and dyspnea. From the
EBM perspective, laboratory outcomes such as FEV1
are surrogates and of secondary importance. Postexer-
cise FEV1 decline and postexercise respiratory symptoms
are poorly correlated [4,6,7]. Therefore, the effects of vita-
min C administration on respiratory symptoms caused by
exercise is an important question that should be concur-
rently considered along with its effects on the pulmonary
function test values. None of the three trials on vita-
min C and EIB recorded respiratory symptoms associ-
ated with the exercise tests (Table 1). Nevertheless,
Tecklenburg et al. did report that asthma symptoms
were less intense after the vitamin C administration
period compared with the placebo period [51].
Five separate randomized placebo-controlled trials re-
ported the effects of vitamin C on respiratory symptoms
during and after heavy physical stress and, according to
a meta-analysis, vitamin C administration decreased the
incidence of respiratory symptoms in these studies by
52% (95% CI: 36% to 65%) [65,66]. Three of the studies
were conducted on marathon runners [67-69], one study
used Canadian soldiers on a winter exercise [70], and
one study was on schoolchildren in a skiing camp in the
Swiss Alps [71]. In the general population, acute cough
and sore throat usually indicates a viral etiology, and au-
thors of these five trials assumed that the respiratory
symptoms were caused by viruses. However, when such
symptoms occur after a marathon run and other endur-
ance sports sessions, they are not always caused by a
viral infection. Instead they can result from an injury to
the airway epithelium caused by hours of exceptional
ventilatory exertion [1-3,72]. Respiratory symptoms as-
sociated with physical irritation of the airways, allergy,
and viral infections are all similar [66,73], and therefore
there is no justification to assume that all the respiratory
symptoms in the above-mentioned five studies werecaused by viruses. In one study, 70% of respiratory
symptom episodes of elite athletes were caused by a
non-infectious etiology, which indicates high preva-
lence of respiratory symptoms not caused by viruses in
athletes [74].
In their study on marathon runners, Peters et al. [67]
recorded the “self-reported symptoms including a run-
ning nose, sneezing, sore throat, cough” during a 2-week
period after the race [67]. The incidence of post-race
cough was reduced by 71% in the vitamin C group as
compared to the placebo group (P[2-t] =0.014; 4/43 vs.
13/41). The incidence of sore throat was reduced by 67%
in the vitamin C group (P =0.001; 8/43 vs. 23/41). In
contrast, vitamin C had no significant effect on the inci-
dence of runny nose (P =0.2; 13/43 vs. 19/41), which is
the most bothersome symptom of rhinovirus infections
[75]. Peters et al. did not carry out any virologic or pul-
monary function tests and therefore the etiology of the
cough and sore throat in the marathon runners is uncer-
tain [67]. It is plausible that the common cold studies on
marathon runners may have been partly measuring the
effect of vitamin C on the epithelial injury caused by the
heavy exertional ventilation.
A recent randomized trial in Israel found that vitamin
C shortened the duration of respiratory symptoms in
male adolescent competitive swimmers by 47% (95% CI:
14% to 80%), but no effect was seen in their female
counterparts [76]. The difference found between the
sexes in that study was significant (P =0.003). Here too,
the etiology was not investigated and the respiratory
symptoms might have been partly caused by the non-
infectious irritation of swimmers’ airways [77].
Thus, in six randomized trials vitamin C reduced the inci-
dence and duration of respiratory symptoms caused by
heavy physical activity, yet it is not clear to what extent the
symptoms were caused by non-infectious injury to the air-
way epithelium as opposed to viral infections. Irrespective of
the etiology, symptoms are more important from the EBM
point of view than laboratory measurements such as FEV1.
Figure 3 (See legend on next page.)
Hemilä Allergy, Asthma & Clinical Immunology 2014, 10:58 Page 7 of 11
http://www.aacijournal.com/content/10/1/58
(See figure on previous page.)
Figure 3 Effect of vitamin C on 0-min postexercise changes for different pulmonary function outcomes according to the study by
Schlesinger and Schachter [56]. Effect of vitamin C on the following immediately (0 min) after exercise: A) the postexercise FEV1 change, B) the
postexercise PEF change, C) the postexercise FEF60 change, and D) the postexercise FEF60 level. Figures 3A, B, and C show the effect of vitamin C
in percentage points (pp). For example, on the placebo-day, participant #11 had a postexercise FEV1 change of -11%, and on the vitamin C day a
postexercise FEV1 change of +19%, which gives the 30 pp improvement shown in Figure 3A. Figure 3D shows the effect of vitamin C in percentages.
For example, on the placebo-day, participant #11 had a postexercise FEF60 level of 2.2 L/s, and on the vitamin C day a postexercise FEF60 level of 2.9 L/s, which
gives the 32% increase shown in Figure 3D. Figure 3 uses the same identification numbers for participants as those used in the original paper [56]. The dash
lines indicate equality between vitamin C and placebo. If vitamin C had no effect, the observations would be located randomly and symmetrically around
the dash lines. The continuous lines indicate the regression lines. In Figure 3A, addition of the placebo-day postexercise FEV1 change to the model containing
the intercept improved the model fit by χ2(1 df) =8.2 (P =0.004). In Figure 3B, addition of the placebo-day postexercise PEF change to the model containing
the intercept improved the model fit by χ2(1 df) =10.8 (P =0.001). In Figure 3C, addition of the placebo-day postexercise FEF60 change to the
model containing the intercept improved the model fit by χ2(1 df) =5.7 (P =0.02) and in Figure 3D, addition of the placebo-day postexercise
FEF60 level to the model containing the intercept improved the model fit by χ
2(1 df) =11.4 (P =0.001). For the statistical methods of Figure 3,
see Additional file 2.
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Asthma is a heterogeneous syndrome, an “umbrella con-
cept,” that includes different phenotypes with different
underlying pathophysiologies [78,79]. Therefore, it is
relevant to consider whether the effects of vitamin C are
limited to EIB or whether vitamin C might also influ-
ence other asthma phenotypes. There is evidence that
some virus infections cause a transient increase in oxida-
tive stress [80,81], and a systematic review identified
three studies that indicated that vitamin C might protect
against common cold-induced asthma [82].
A 4-month trial on 154 British asthmatics showed that
the FEV1 level was not influenced by 1 g/day of vitamin
C [83]. Moreover, the FEV1 level was not influenced by a
5-year administration of 0.25 g/day of vitamin C along
with vitamin E and β-carotene in a large-scale trial on
20,536 British adults [84]. These two British-based stud-
ies imply that vitamin C supplementation does not influ-
ence pulmonary functions in patients with stable asthma
or in relatively healthy people. Nevertheless, the study
on British asthmatics found that the need for inhaled
corticosteroids was lower in the vitamin C group [85]. In
any case, vitamin C may beneficially influence pulmon-
ary functions of some people under certain forms of
acute stress, such as when they endure heavy physical
activity or suffer from a viral respiratory tract infection.
Refocusing research onto the biological effects of
vitamin C
Vitamin C was identified in the search for the substance
the deficiency of which led to scurvy. These early studies
led to the assumption that the sole physiological func-
tion of vitamin C is just to prevent and treat scurvy.
Therefore, it is often assumed that higher doses of vita-
min C have no benefit when a person does not suffer
from scurvy. In view of this strongly entrenched as-
sumption, assessing the role of vitamin C on diseases
and conditions other than scurvy is not just an empirical
question but also a conceptual issue.Bias against vitamin supplementation in general has
been well documented [86-88]. Several influential reviews
on vitamin C and the common cold have been shown to
be erroneous and misleading [89,90]. A Cochrane review
on vitamin C and asthma [91] was shown to have substan-
tial errors in the extraction of data and data analysis, and
the review misled readers for a decade [92,93]. If we wish
for progress in the understanding of the effects of vitamin
C on EIB, it needs to be acknowledged that the effects of
vitamin C are not limited to the prevention of scurvy
alone and, consequently, the published data on vitamin
C should be analyzed carefully and comprehensively.
Conclusions
Three trials have examined the effect of vitamin C on
EIB and found that 0.5 to 2 g/day vitamin C halved the
postexercise FEV1 decline (Figure 1). In addition, five tri-
als found that vitamin C administration halved the inci-
dence of respiratory symptoms after short-term heavy
physical stress [65,66] and one other trial found that
vitamin C administration halved the duration of the re-
spiratory symptoms in male adolescent competitive
swimmers [76]. Although these nine randomized trials
indicate that vitamin C has genuine biological effects on
pulmonary functions and respiratory symptoms in people
doing heavy exercise, it is unclear how the effect of
vitamin C depends on the kind of physical activity, the
level of physical activity, the temperature of ambient
air, the humidity of ambient air, the dose of vitamin C,
the level of dietary intake of vitamin C, and various
other factors.
Given the safety and low cost of vitamin C, and the
consistency of positive findings in the nine randomized
trials on vitamin C against EIB and respiratory symp-
toms, it seems reasonable for physically active people to
test whether vitamin C is beneficial on an individual
basis, if they have documented EIB or suffer from re-
spiratory symptoms such as cough or sore throat after
taking vigorous exercise.
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http://www.aacijournal.com/content/10/1/58In future studies on vitamin C and EIB, a variety of pul-
monary function outcomes should be measured. Although
FEV1 is currently the standard measure for diagnosing
EIB, the effect of vitamin C on the postexercise FEF50 and
FEF75 levels should also be examined, as they may provide
important additional information (Figures 2D and 3D).
Furthermore, PEF is much easier to measure than carrying
out a spirometry test. Therefore the possibility that the
postexercise PEF decline might identify those people who
may benefit from vitamin C administration should be in-
vestigated (Figures 2B and 3B).
In the earlier studies on vitamin C and EIB, only the
mean effects on FEV1 were calculated [51,56] or EIB was
dichotomized by an arbitrary cut off level [57]. However,
postexercise FEV1 decline is a continuous variable and
the effect of vitamin C may depend on the baseline level
of pulmonary function decline. Therefore, linear model-
ling is a much more informative way to analyze vitamin
C effects on pulmonary functions and it should be used
in the future studies (Figures 2 and 3). Finally, while pul-
monary function tests are objective outcomes, symptoms
are much more relevant outcomes from the EBM point
of view, therefore both of them should be recorded con-
currently in future investigations.
Additional files
Additional file 1: Methods for Figure 2 (5 min data ) and
Figures 2E and 2F.
Additional file 2: Methods for Figure 3 (0 min data) and
Figures 3E and 3F.
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